Headquarter
San Francisco, USA

Milestones
Founded: 2018
Invested: 2026

CEO
Amber Salzman, CEO

Vertical
Biotech

Website

Linkedin

Epicrispr Biotechnologies is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.

Related news:

Angelini Ventures Invests in Epicrispr Biotechnologies' $90M Series C to Advance First-in-Class Epigenetic Therapy for FSHD